TPI
NBIX icon

Trust Point Inc’s Neurocrine Biosciences NBIX Stock Holding History

Trust Point Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
+1,455
New +$216K 0.02% 398
2025
Q4 		– Sell
-1,685
Closed -$237K – 494
2025
Q3 		$237K Buy
+1,685
New +$228K 0.02% 430
2025
Q2 		– Sell
-1,823
Closed -$202K – 449
2025
Q1 		$202K Sell
1,823
-660
-27% -$83.6K 0.02% 442
2024
Q4 		$339K Buy
2,483
+548
+28% +$67.8K 0.02% 391
2024
Q3 		$223K Buy
1,935
+349
+22% +$47.8K 0.02% 475
2024
Q2 		$218K Buy
+1,586
New +$218K 0.02% 461

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Trust Point Inc's NBIX Position: Q2 2026 in Review

Trust Point Inc opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,455 shares worth $245K. The stake represents 0.02% of the portfolio and ranks #398 among its holdings. This is a return to the name: Trust Point Inc previously reported a position in NBIX as recently as Q3 2025.

Trust Point Inc first reported a position in NBIX in Q2 2024 and has held it in 6 quarters since. The position peaked at $339K in Q4 2024. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Trust Point Inc held 1,455 shares of Neurocrine Biosciences worth $245K as of Q2 2026.
  • Neurocrine Biosciences was a new Trust Point Inc position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Trust Point Inc's portfolio in Q2 2026, its #398 holding.
  • Trust Point Inc first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 6 quarters since.
  • Trust Point Inc's Neurocrine Biosciences position peaked at $339K in Q4 2024.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Trust Point Inc's 13F filing for Q2 2026, filed 8 Jul 2026.